Voyager Therapeutics (VYGR)
Develops CNS gene therapies and antibodies around TRACER delivery and tau biology.
Something off on this page? Send us feedback.
Develops clinical-stage neurogenetic medicines for neurological diseases, led by tau programs for Alzheimer's disease and a TRACER brain-delivery platform. The portfolio has no approved commercial medicines, mixes wholly owned and partnered CNS programs, and depends on clinical data, regulatory progress, collaboration funding, and continued access to capital.
Builds disease-modifying neurotherapeutics around CNS delivery and human genetics. The current portfolio centers on VY7523, an anti-tau antibody, and VY1706, a tau-silencing gene therapy, with APOE gene therapy and earlier research extending the Alzheimer's focus.
TRACER supplies the delivery platform: RNA-based screening for AAV capsids designed to cross the blood-brain barrier and reach CNS tissue. Partnered programs with Neurocrine, Novartis, Alexion, and Transition Bio add rare-neurology and CNS targets such as NBIB-223, GBA1, and TDP-43.
Operations are concentrated in the United States from Lexington, Massachusetts, with no approved commercial medicines. The business depends on clinical readouts, IND and trial execution, partner choices, reimbursement of collaboration work, and financing before product revenue can begin.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $116.3M · Total debt $32.6M · Total assets $197.8M · Shareholders' equity $154.4M
- Revenue
- $3.2M
- Operating income
- −$26.4M
- Net income
- −$24.5M
No dividends on record.
| Institutions | ≈ 57.02% | 35.14M shares | |
|---|---|---|---|
| 144 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.21% | 1.36M shares | |
| 8 holders · as of May 18, 2026 | |||
| Strategic holders | 5.42% | 3.34M shares | |
| 1 holder · as of Jan 26, 2026 | |||
| Other | ≈ 35.35% | 21.78M shares | |
| remainder | |||
61.62M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.39% | 5.17M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 7.21% | 4.44M | as of Jun 30, 2026 |
Armistice Capital, LLCInstitution | 5.58% | 3.44M | as of Jun 30, 2026 |
Integrated Core Strategies (US) LLCStrategic | 5.42% | 3.34M | filed Jan 26, 2026 |
Vestal Point Capital, LPInstitution | 4.26% | 2.63M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 2, 2026 | Alfred Sandrock | director, officer: President and CEO | −11,511 | $3.87 |
| Feb 24, 2026 | Todd Alfred Carter | officer: Chief Scientific Officer | −4,174 | $3.76 |
| Feb 24, 2026 | Nathan D. Jorgensen | officer: Chief Financial Officer | −4,668 | $3.77 |
| Feb 24, 2026 | Alfred Sandrock | director, officer: President and CEO | −14,197 | $3.79 |
| Feb 24, 2026 | Robin Swartz | officer: COO & CBO | −6,458 | $3.77 |
- Denali Therapeutics
BBB-delivery and tau programs in neurodegeneration
- Ionis Pharmaceuticals
Tau antisense and neurology RNA medicines
- AC Immune
Tau-focused Alzheimer's immunotherapy and diagnostics peer
- Biogen
Commercial-scale Alzheimer's and tau-ASO rival
- Lexeo Therapeutics
APOE Alzheimer's and genetic-medicine pipeline overlap
- uniQure
CNS AAV gene-silencing competitor
- Passage Bio
Focused CNS AAV programs for neurodegeneration
- REGENXBIO
NAV AAV platform and rare-CNS gene-therapy peer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Voyager Therapeutics | $3.00 | −4.62% | $189.7M | — | — | 5.5 | −39.1% |
| Denali Therapeutics | $20.76 | −3.89% | $3.43B | — | — | 951.2 | — |
| Ionis Pharmaceuticals | $43.56 | −4.80% | $7.60B | — | — | 8.7 | −40.7% |
| AC Immune | $2.83 | +3.48% | $277.8M | — | — | 13.1 | +823.6% |
| Biogen | $224.68 | −0.30% | $33.30B | 39.9 | 16.9 | 3.3 | +3.4% |
| Lexeo Therapeutics | $3.68 | −9.58% | $319.6M | — | — | — | — |
| uniQure | $43.12 | −4.77% | $3.14B | — | — | 168.2 | +11.0% |
| Passage Bio | $4.82 | −2.63% | $15.9M | — | — | — | — |
| REGENXBIO | $7.66 | −6.01% | $421.3M | — | — | 2.4 | +405.7% |
| Median | 39.9 | 16.9 | 10.9 | +11.0% |